Menu
Recruiting NCT07410793

Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis.

Phase II Interventional Plaque Type Psorisis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Acupuncture, Calcipotriol 0.005% ointment, Chinese herb cream.
Who it may be relevant to
Registry conditions: Plaque Type Psorisis. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Thailand
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Comparative Efficacy of Acupuncture Combined With Chinese Herbal Cream and Acupuncture Combined With Calcipotriol for Plaque Psoriasis.

Overview

Clinical trial which compares 2 treatment methods (1) Acupunture with a Chinese Herbal Cream and (2) Acupuncture with the standard treatment "calcipotriol" for patients with plaque psoriasis.

Interventions

  • Procedure Acupuncture
    Bai-Hui (GV20), Fei-Shu (BL13), Ge-Shu (BL-17), Qu-Chi (LI11), Zu-San-Li (ST36), He-Gu (LI4), Tai-Chong (LR3), San-Yin-Jiao (SP6), Wei-Zhong (BL40)
  • Drug Calcipotriol 0.005% ointment
    Calcipotriol 0.005% ointment
  • Drug Chinese herb cream
    Main API : Sophora flavescens Ait. (Ku-Shen), Cnidium monnieri (L.) Cuss. (She-Chuang-Zi), Prunus mume (Sieb.) Sieb.et Zucc. (Wu-Mei), Dictamnus dasycarpus Turcz. (Bai-Xian-Pi), Rheum palmatum L. (Da-Huang)

Primary outcome measures

  • Psoriasis Area and Severity Index, PASI score [Time frame: 8 weeks]
Secondary outcome measures (1)
  • Dermatology Life Quality Index (DLQI) [Time frame: 8 weeks]

Eligibility criteria

Inclusion criteria

  • Plaque psoriasis on skin, scalp, or nails
  • Not receive any psoriasis treatment at least 4 weeks prior to the study
  • ≤10% body surface area (BSA), PASI≤10, DLQI≤10

Exclusion criteria

  • Pregnancy and lactation
  • Other type of psoriasis i.e. Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis
  • Uncontrollable diseases i.e. CVS, liver, kidney, cancer
  • Using anticoagulants i.e. Aspirin, Warfarin, Clopidogrel, Dabigatran, Riavaraxaban, Apixaban, Heparin
  • Treated with psoriasis biologic agents in the past 6 months
  • Needle phobia
  • Receiving immunosuppresive agents i.e. systemic corticosteroid, NSAIDs, chemotherapeutic agents
  • Participating in other clinical study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Thailand · 1 center
  • Mae Fah Luang University — Muang

Identifiers

NCT: NCT07410793 · EC 25228-25

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗